Addressing the growing burden of non-communicable disease by leveraging lessons from infectious disease management. by Piot, Peter et al.
Piot, P; Caldwell, A; Lamptey, P; Nyrirenda, M; Mehra, S; Cahill, K;
Aerts, A (2016) Addressing the growing burden of non-communicable
disease by leveraging lessons from infectious disease management.
Journal of global health, 6 (1). 010304. ISSN 2047-2978 DOI: 10.7189/jogh.06.010304
Downloaded from: http://researchonline.lshtm.ac.uk/2537479/
DOI: 10.7189/jogh.06.010304
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
V
IE
W
PO
IN
TS
I
n recent decades, low– and middle–income countries 
(LMICs) have achieved decreased morbidity and mor-
tality associated with infectious diseases and poor ma-
ternal– and child–health (MCH). However, despite these 
advances, LMICs now face an additional burden with the 
inexorable rise of non–communicable diseases (NCDs).
Deaths due to NCDs in LMICs are expected to increase 
from 30.8 million in 2015 to 41.8 million by 2030 [1]. 
While improvements in life expectancy, lifestyle and ur-
banisation go some way to explaining why more people in 
LMICs are affected by NCDs, it is less clear why these pop-
ulations are contracting NCDs at a younger age and with 
worse outcomes than in high–income countries (HICs) [2]. 
Despite having a lower cardiovascular disease risk factor 
burden, LMIC populations have a four–fold higher mortal-
ity rate from cardiovascular events than HIC populations 
[3] in part due to a lack of access to quality, integrated 
health services and the poor availability of early interven-
tions and effective NCD prevention programmes. The HIV/
AIDS epidemic was the last time the world confronted a 
global health challenge that so disproportionately caused 
premature adult deaths in LMICs.
The conclusion is unavoidable: the time to act is now. Pre-
vention of NCDs at a population and an individual level is 
key and requires policy and structural changes. We have a 
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unique opportunity to learn from the successes of infec-
tious disease control programmes in LMICs and leverage 
these to address the growing NCD burden. Translatable 
learnings include: 1) emphasizing primary prevention, par-
ticularly in those at highest risk; 2) targeting service deliv-
ery to high–risk populations; 3) enabling access to ade-
quate, affordable care at community level; 4) engendering 
patient empowerment and involving people affected by 
chronic conditions; 5) enabling access to quality drugs and 
adherence programmes; 6) regularly measuring the effec-
tiveness and impact of programmes to ensure their appro-
priateness and improvement; and 7) creating an environ-
ment of health financing for universal coverage.
Innovations to counter the emerging NCD epidemic 
must encompass both prevention and the delivery of 
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Addressing the growing burden 
of non–communicable disease 
by leveraging lessons from 
infectious disease management
Despite advances in decreasing morbidity and 
mortality associated with infectious diseases 
and poor maternal– and child–health low– and 
middle–income countries now face an addi-
tional burden with the inexorable rise of non–
communicable diseases.
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care. Infectious disease programmes have used task–shift-
ing, where less skilled health workers and community 
members are involved in delivery of health services. In In-
dia, we have seen this used for NCDs in the Arogya Kiran 
model where the existing health workforce was over-
stretched. Volunteers and teachers successfully delivered 
diabetes and hypertension screening and management to 
over 600 000 people [4]. Patient empowerment, and com-
munity involvement in health care delivery and gover-
nance, will be critical in tackling NCDs, since most are 
chronic conditions, which initially present silently and re-
quire long–term management [5].
In Malawi, recognizing the close relationship of HIV infec-
tion and cardiovascular diseases has led to screening for 
hypertension being integrated into HIV care [6]. In Ghana, 
decentralised community–based hypertension care, using 
digital technology, is helping to empower patients to man-
age their own disease: a model that is again adapted from 
HIV management [7]. We are also starting to see examples 
in India of MCH care coupled with life–long NCD screen-
ing and awareness programmes [8].
While these examples of managing the dual burden of in-
fectious diseases and NCDs are encouraging, more needs 
to be done. The largest gap is in NCD prevention. Tack-
ling the obesity epidemic and wrestling with the issues 
around curbing tobacco sales and smoking are rightly 
high on the NCD prevention agenda. The greatest oppor-
tunity is preventing a tobacco–related epidemic in sub–
Saharan Africa where smoking levels are still low. Health 
budgets and development assistance for health must al-
locate resources commensurate with the dual disease bur-
den. Health spending of governments in LMICs has tri-
pled over the past 20 years, but remains low [9]. In 
addition, more health care models should consider diver-
sified revenue streams or hybrid financing (eg, tiered pay-
ment schemes) to ensure sustainability. If equity is to be 
improved, patients need access to quality health care, 
through sustainable health–financing systems for univer-
sal health coverage, while reducing out–of–pocket expen-
diture for the under–served population.
Implementing such models will require strong government 
leadership and interventions, and partnerships across the 
public and private sectors. Some public–private partner-
ships (PPPs) in infectious diseases have demonstrated their 
potential to catalyze the delivery of, and access to, preven-
tion and care through providing 
complementary strengths [10]. 
The private sector draws on its 
business and scientific expertise, 
focusing on strong results–based 
operations, whereas the public sec-
tor brings a wealth of expertise in 
implementation with equity, man-
agement and documentation.
The end–users of the services, in-
cluding patients and health care 
providers, also need to be includ-
ed from the outset to ensure that 
the models are people–centered, 
co–created, adapted to prevailing 
contextual nuances, and sustain-
able. If we build on what we have 
learnt from infectious disease 
management, we could have a 
transformational impact on the 
growing NCD burden.
We have a unique opportunity to learn from 
the successes of infectious disease control 
programmes and leverage these to address the 
growing non–communicable disease burden: 
1) emphasizing primary prevention; 2) target-
ing service delivery to high–risk populations; 
3) enabling access to adequate, affordable
care; 4) engendering patient empowerment; 
5) enabling access to quality drugs and adher-
ence programmes; 6) regularly measuring the 
effectiveness and impact of; and 7) creating an 
environment of health financing for universal 
coverage.
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